15 active not recruiting. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Active not recruiting 15 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2025-07-08 | 2026-10-15 |
| An Open-Label Study of Azetukalner in Major Depressive Disorder Azetukalner - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 460 | 2025-03-18 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2024-12-20 | 2026-10-13 |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression psilocybin - Refractory Depression, Treatment Resistant Depression | Phase 3 | Active not recruiting | University of North Carolina, Chapel Hill | 20 | 2024-04-19 | 2026-05-06 |
| Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury Iltamiocel, Placebo - Fecal Incontinence | Phase 3 | Active not recruiting | Cook MyoSite | 200 | 2024-03-21 | 2026-10-20 |
| Improving Outcomes in Depression in Primary Care in a Low Resource Setting Healthy Activity Program (HAP), Antidepressant medication (fluoxetine) - Depression, Depressive Disorder | Phase 3 | Active not recruiting | Harvard Medical School (HMS and HSDM) | 1500 | 2024-03-18 | 2026-05-22 |
| Psilocybin for Major Depressive Disorder (MDD) Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg - Depressive Disorder, Major | Phase 3 | Active not recruiting | Usona Institute | 238 | 2024-03-13 | 2026-10-21 |
| Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors Memantine, ComB Behavioral Therapy - Skin-Picking, Trichotillomania (Hair-Pulling Disorder) | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 26 | 2023-08-02 | 2026-07-07 |
| Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women MWSH plus Candlelit Care, MWSH - Pregnancy Related, Pregnancy Complications | Phase 2 / Phase 3 | Active not recruiting | Cedars-Sinai Medical Center | 150 | 2023-06-01 | 2026-10-22 |
| Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer Melatonin, Placebo for Melatonin, Methylphenidate - Sleep, Fatigue | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 169 | 2022-11-21 | 2026-09-25 |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Masupirdine 50 mg, Masupirdine 100 mg, Placebo - Agitation, Alzheimer's Type Dementia | Phase 3 | Active not recruiting | Suven Life Sciences Limited | 375 | 2022-11-01 | 2026-09-15 |
| Goal-Directed Sedation in Mechanically Ventilated Infants and Children Dexmedetomidine, Midazolam - Delirium, Critical Illness | Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 372 | 2021-05-10 | 2026-10-20 |
| Neostigmine and Glycopyrrolate by Iontophoresis Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics - Spinal Cord Injuries, Constipation | Phase 3 | Active not recruiting | James J. Peters Veterans Affairs Medical Center | 6 | 2020-11-06 | 2024-04-08 |
| Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence AMDC-USR (iltamiocel), Placebo - Stress Urinary Incontinence | Phase 3 | Active not recruiting | Cook MyoSite | 96 | 2019-04-23 | 2026-10-21 |
| Escitalopram for Agitation in Alzheimer's Disease Escitalopram, Placebo - Dementia | Phase 3 | Active not recruiting | JHSPH Center for Clinical Trials | 187 | 2018-01-03 | 2025-01-31 |
Depression (8) · Depressive Disorder, Major (4) · Psychomotor Agitation (3) · Anxiety Disorders (2) · Encopresis (2) · Fecal Incontinence (2) · Alzheimer Disease (1) · Constipation (1) · Critical Illness (1) · Delirium (1) · Dementia (1) · Depression, Postpartum (1) · Depressive Disorder (1) · Depressive Disorder, Treatment-Resistant (1) · Excoriation Disorder (1)
Behavior (15) · Mental Disorders (14) · Pathological Conditions, Signs and Symptoms (8) · Mood Disorders (7) · Signs and Symptoms (7) · Depressive Disorder (6) · Nervous System Diseases (4) · Aberrant Motor Behavior in Dementia (3) · Dyskinesias (3) · Elimination Disorders (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Psychomotor Disorders (3) · Central Nervous System Diseases (2)
Psilocybin (2) · XEN1101 (2) · 1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate (1) · Antidepressive Agents (1) · Cognitive Behavioral Therapy (1) · Dexmedetomidine (1) · Escitalopram (1) · Fluoxetine (1) · Glycopyrrolate (1) · Iontophoresis (1) · Melatonin (1) · Memantine (1) · Methylphenidate (1) · Midazolam (1) · Psychiatric Rehabilitation (1)
Xenon Pharmaceuticals Inc. (3) · Cook MyoSite (2) · Cedars-Sinai Medical Center (1) · Harvard Medical School (HMS and HSDM) (1) · JHSPH Center for Clinical Trials (1) · James J. Peters Veterans Affairs Medical Center (1) · M.D. Anderson Cancer Center (1) · Suven Life Sciences Limited (1) · University of Chicago (1) · University of North Carolina, Chapel Hill (1) · Usona Institute (1) · Vanderbilt University Medical Center (1)
United States (14) · Poland (3) · Finland (2) · Canada (1) · Croatia (1) · Germany (1) · India (1) · Romania (1) · Serbia (1) · Slovakia (1) · Spain (1) · United Kingdom (1)
Charles Raison, MD (1) · Christopher P Cardozo, MD (1) · Constantine Lyketsos, MD, MHS (1) · Gregory Chasson, PhD (1) · Heidi Smith, MD, MSCI (1) · Jon E Grant, MD, JD, MPH (1) · Melissa Kaufman, M.D., Ph.D. (1) · Robert K McClure, MD (1) · Ron Jankowski, PhD (1) · Sriram Yennu, MD (1) · Vikram Patel, MD (1)
PMID 31587995, PMID 39804360, PMID 40133524, PMID 40470239, PMID 40739549
R01AG052510 (1), R01MH121632 (1), R21MD017396 (1), R61HL151951 (1)